drugset / Trial / NCT00002440

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002440

Phase 2 Completed 80 enrolled Glaxo Wellcome
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give 1592U89 plus certain protease inhibitors (PIs) to HIV-infected patients who never have been treated with anti-HIV drugs. This study also examines how the body processes these drugs when they are given together.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified
Subject Amprenavir Other / unclassified
Subject INDINAVIR ANHYDROUS Other / unclassified
Subject Nelfinavir Other / unclassified
Subject Ritonavir Other / unclassified
Subject Saquinavir Small molecule